Pat R. Brady

Twinstrand Therapeutics Inc. manufactures and distributes biological drugs. It focuses on discovering, developing and commercializing of therapeutics for the treatment of cancer, hepatitis A, cytomegalovirus, malaria, schistosomiasis, and fungal diseases. The company was founded in 1995 and is located in North Vancouver, Canada.

Valocor Therapeutics is a clinical-stage, privately-held company dedicated to developing innovative treatments for major unmet needs in dermatology. The company's portfolio of dermatology therapeutics includes Lemuteporfin, a potent and selective topical photodynamic therapy for moderate to severe acne and a portfolio of novel, topical small molecule therapeutics targeting acne, sebaceous gland hyperactivity, skin pigmentation disorders and inflammatory skin diseases. Valocor Therapeutics is headquartered in Vancouver, British Columbia. Although many common yet serious skin conditions have unsatisfactory treatment options, dermatology has in recent years attracted limited research resources and investment. As a result, a sparse pipeline and a lack of true scientific innovation have been the dominant themes of this field for the last twenty years. During this same period, technological advances have produced new research techniques that have greatly expanded its ability to study disease processes and establish new effective therapeutic strategies. Much of this innovative research has been applied to the fields such as oncology, autoimmunity, and ocular diseases. Valocor is applying current biotechnology techniques to develop breakthrough therapies for major dermatological diseases, where prevalent conditions, minimal competition and important medical needs exist.

OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA.

Protiva Biotherapeutics, Inc. develops pharmaceutical products for human diseases. The firm offers drugs for cancer, influenza (including H5N1), Ebola, inflammatory diseases and other chronic viral infections. The company was founded in September, 2000 and is headquartered in Seattle, WA.

Dynamotive Energy Systems Corp. provides energy solutions. Its carbon and greenhouse gas neutral fast pyrolysis technology uses medium temperatures and oxygen-less conditions to turn dry, waste cellulosic biomass into BioOil and Bio Char. The firm develops an upgrading process to produce transport fuels from pyrolysis oils. The company was founded in 1990 and is headquartered in Vancouver, Canada.

MSI Methylation Sciences, Inc. engages in drug development through compound leverage. It focuses on developing pharmaceuticals based on molecules with proven efficacy that are under exploited in pharmaceutical markets. The firm offers s-adenosyl methionine, is a prescription drug used as a dietary supplement. The company was founded by Barry J. Guld and Nancy Harrison in 2006 and is headquartered in Burnaby, Canada.

Celator Pharmaceuticals Corp. is an oncology-based biopharmaceutical company. It focuses on a proprietary technology platform which evaluates combinations of anti-cancer drugs for enhanced anti-cancer activity. The company was founded by Lawrence David Mayer and is headquartered in Vancouver, Canada.

Inimex Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of Innate Defense Regulators (IDRs). IDRs are novel drugs that selectively trigger the body's innate defenses, protecting against antibiotic-resistant infections and controlling inflammation. The company was founded in 2001 and is headquartered in Vancouver, Canada.